Partner With Us

Rna Diagnostics is working with physicians worldwide to improve cancer treatment and quality of life for patients.

 

We welcome inquiries from clinicians interested in collaborative trials using our VERIDAPT DX™ technology to assess solid tumor response to early cancer drug treatment.

Real-time Response Monitoring

VERIDAPT DX measures the degree of RNA (rRNA) disruption in solid tumor cells during neoadjuvant treatment, a predictive biomarker of impending cell death. Learn more about VERIDAPT DX technology.

Increasing evidence for clinical effectiveness

A series of pre-clinical studies, and retrospective and ongoing prospective clinical data has shown strong evidence for clinical effectiveness.

A large-scale validation study is now under way in seven countries – the Breast Cancer Response Evaluation for Individualized Therapy (BREVITY) clinical trial.

Phase 1 results, published in JNCI Cancer Spectrum, demonstrate VERIDAPT DX’s strong capability (Negative Predictive Value >93%) to accurately predict therapy efficacy/outcomes during early treatment, allowing oncologists to personalize and optimize patient care.

Potential application to any solid tumor

Our initial focus is on primary breast cancer; however, our assay platform has the potential to apply to any solid tumor and any cancer drug therapy for personalized, precision medicine.

Connect with us to explore collaborative opportunities for VERIDAPT DX predictive biomarker technology